Sanofi

This study tests a new mRNA vaccine designed to prevent chlamydia, a common sexually transmitted infection. About 1,560 adults aged 18 to 29 who are at higher risk of infection will receive either a low, medium, or high dose of the vaccine or a placebo. Researchers will monitor s…

This early-stage study tests the safety and immune response of experimental vaccines for respiratory syncytial virus (RSV) and a type of bird flu (H5N1) in 570 healthy adults aged 18 to 49. Participants will receive one or two shots, and researchers will monitor side effects and …

This study tests a new 21-valent pneumococcal vaccine (PCV21) in 100 children aged 2 to 17 with sickle cell disease, who are at high risk for serious infections. Researchers will compare PCV21 to a licensed vaccine to see if it is safe and helps the body produce protective antibo…

This study tests a new yellow fever vaccine (vYF) in about 2,440 healthy children aged 9 months to 5 years. Researchers want to see if vYF is as safe and effective at creating antibodies as two existing vaccines. Some children will also get the MMR vaccine at the same time. The s…

This study tests an experimental drug called SAR442970 in adults with moderate to severe Crohn's disease. About 99 participants will receive either the drug or a placebo to see if it can reduce gut inflammation. The study lasts up to 168 weeks, with an option to continue the drug…

This study tests a drug called teplizumab in people aged 1 to 25 who were recently diagnosed with type 1 diabetes. The goal is to see if teplizumab can help control blood sugar and reduce the need for insulin at mealtimes. Participants will receive either teplizumab or a placebo …

This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) in people aged 16 to 75 with two rare kidney diseases, FSGS or MCD. The goal is to see if these drugs can reduce protein in the urine, a sign of kidney damage, and help achieve remission. Partic…

This study tests a new drug called SAR445399 for people with moderate to severe hidradenitis suppurativa (HS), a skin condition causing painful lumps. About 144 adults will receive either the drug or a placebo for 32 weeks to see if it reduces the number of abscesses and inflamed…

This study compares a new drug, frexalimab, to the standard drug tacrolimus in 526 adults receiving their first kidney transplant. The goal is to see if frexalimab is better at preventing organ rejection and has fewer side effects over 5 years. Participants must have low to moder…

This study tests a new antibody drug (SAR446523) given as a shot under the skin for people with multiple myeloma that has come back or stopped responding to treatment. The goal is to find the safest and most effective dose, and to see if it can shrink tumors. About 87 adults will…

This study tests a new drug called SAR442970 for people with moderate to severe ulcerative colitis, a condition that causes inflammation in the colon. About 99 adults aged 18 to 75 will receive either the drug or a placebo to see if it can help control the disease. The study last…

This study tests if a shot under the skin (subcutaneous) of the drug frexalimab works as well as the IV version for people with multiple sclerosis. About 160 adults aged 18-60 will receive either the shot or the IV every 4 weeks for 48 weeks. The goal is to see if the shot is a s…

This study tests two doses of rilzabrutinib in 30 adults with Graves' disease, an autoimmune condition causing an overactive thyroid. The goal is to see if the drug can safely lower thyroid hormone levels and improve symptoms, including eye problems. Participants take the drug fo…

This early-stage study tests a new medicine, SAR448501/DR-0201, in adults with lupus or rheumatoid arthritis. The goal is to find safe and tolerable doses by checking side effects and how the drug works in the body. About 62 participants will receive multiple doses and be followe…

This study tests a drug called frexalimab in 192 people recently diagnosed with type 1 diabetes who are already using insulin. The goal is to see if it can help the pancreas keep making some insulin naturally, reducing the amount of insulin needed. Participants will receive eithe…

This study tests a drug called duvakitug in people with moderate-to-severe ulcerative colitis who have already responded to treatment. The goal is to see if duvakitug can help maintain remission over many weeks. About 671 adults will take either the drug or a placebo, with follow…

This study tests a new injectable drug called amlitelimab for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with other biologic or JAK inhibitor treatments. Participants will continue using topical steroids and receive either aml…

This study tests a new drug called brivekimig for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition that causes boils and tunnels. The trial will compare different doses of brivekimig to a placebo over about 48 weeks to see if it reduces skin …

This study tests a new drug called riliprubart in 140 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) that hasn't improved with standard treatments. The drug is compared to a placebo to see if it can reduce disability over 48 weeks. Participants will be follo…

This study is for people with multiple myeloma that has come back or stopped responding to treatment. It tests a drug called isatuximab combined with other new drugs, with or without dexamethasone, to see if these combinations work better than the current standard. About 258 adul…

This study tests a single injection of SAR402663 into the eye for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if one dose can safely control the disease and reduce the need for frequent eye injections. About 66 adults…

This study tests a new way to give the drug isatuximab using a small device worn on the body, along with two other drugs (carfilzomib and dexamethasone), for people with multiple myeloma that has come back or not responded to treatment. The goal is to see if this combination help…

This study tests whether a new drug, SAR445399, can reduce mucus plugs in the lungs of adults with non-cystic fibrosis bronchiectasis. About 70 participants will receive either the drug or a placebo, and researchers will measure changes in mucus plug scores using CT scans over 24…

This study tests a new medicine called lunsekimig in adults aged 40 to 80 with COPD that is not well controlled despite standard treatments. The drug is given as a shot and compared to a placebo to see if it can reduce the number of moderate-to-severe COPD flare-ups over about a …

This study tests an experimental drug called SAR445877 in about 542 adults with advanced solid tumors that have spread or can't be removed. The goal is to find safe doses and see if the drug, given alone or with other cancer treatments, can shrink tumors. The trial has two parts:…

This study tests an oral drug called rilzabrutinib in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants must have failed first-line treatment. The goal is to see if the drug can safely raise platelet …

This study tests an experimental drug called SAR444336 in 54 adults with microscopic colitis who are currently in remission using budesonide (a steroid). The goal is to see if the drug can keep them symptom-free without needing budesonide for 24 weeks. Participants will be random…

This study tests whether dupilumab, an injectable drug, can reduce mucus blockages in the lungs of people with moderate-to-severe COPD. About 218 adults aged 40 to 85 who smoke or used to smoke will receive either dupilumab or a placebo for 24 weeks. The main goal is to see if th…

This study tests a new drug called riliprubart against standard IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition that causes weakness and numbness. About 160 adults who already use IVIg will receive either riliprubart or I…

This study tests an oral drug called belumosudil in adults who have chronic lung allograft dysfunction (CLAD) after a double lung transplant. CLAD is a form of chronic rejection that slowly worsens lung function. The goal is to see if the drug can slow or stop the decline in brea…

This study looks at whether a once-weekly drug called efanesoctocog alfa can reduce swelling in the joints of people with hemophilia A. About 35 participants aged 12 and older with moderate to severe hemophilia A and existing joint swelling will receive the drug for 12 months. Do…

This study tests a single injection of SAR446597 into the eye for people with geographic atrophy, a severe form of dry age-related macular degeneration that causes blind spots. About 104 adults aged 60 and older will join to see if the treatment is safe and can slow vision loss o…

This study tests an investigational drug called lunsekimig in adults with mild-to-moderate asthma who are at high risk for attacks but not eligible for current biologic treatments. About 1,147 participants will receive either the drug or a placebo as an add-on to their usual asth…

This study tests a drug called sarilumab in children aged 1 to 17 with systemic juvenile idiopathic arthritis, a type of arthritis that causes body-wide inflammation. The goal is to find the best dose and see if it safely controls the disease. About 51 participants will receive t…

This study looks at how well a medicine called efanesoctocog alfa works to protect joints and reduce bleeding in people with hemophilia A. About 100 participants in Taiwan will be followed for up to 5 years during their regular clinic visits. The goal is to see if this treatment …

This early-stage study tests a new drug, SAR448501, in about 96 adults with B-cell non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. The main goals are to check the drug's safety and find the best dose. Participants will receive the dr…

This study tests a new drug, duvakitug, in about 980 adults with moderate to severe Crohn's disease who haven't responded well to other treatments. Participants will receive either duvakitug or a placebo for 12 weeks to see if it can reduce symptoms and heal the gut lining. The g…

This study follows 1,000 people with early-stage (Stage 2) Type 1 Diabetes who received teplizumab during routine care. Researchers want to see how long the drug delays progression to full-blown (Stage 3) diabetes and how it affects quality of life. Participants are observed for …

This study tests whether adding the drug sarilumab to a slow steroid taper helps people with early polymyalgia rheumatica (PMR) achieve lasting remission. About 300 adults aged 50 and older with newly diagnosed or early relapsing PMR will receive either a low or high dose of sari…

This study tests a drug called teplizumab in Japanese people aged 8 to 34 who have Stage 2 type 1 diabetes, meaning their blood sugar is starting to rise but they don't need insulin yet. The goal is to see if a 14-day IV treatment can delay or prevent the disease from progressing…

This study follows 200 people with stage 2 type 1 diabetes who take TZIELD to delay the disease. Researchers will watch for side effects, serious events, and effects during pregnancy over many years. The goal is to understand the long-term safety of this treatment in real-world u…

This study tests a medicine called fitusiran in boys aged 1 to under 12 with severe hemophilia A or B, including those whose bodies have developed resistance to standard treatments. The goal is to see if regular shots of fitusiran can reduce the number of bleeding episodes compar…

This study tests an experimental drug called SAR441566 in 260 adults with moderate to severe Crohn's disease. The goal is to see if the drug can reduce inflammation and damage in the intestines better than a placebo. Participants will receive either the drug or a placebo for up t…

This study tests a new medicine called duvakitug for people with moderate to severe Crohn's disease who have already responded to treatment. The goal is to see if duvakitug can help keep the disease in remission longer than a placebo. About 751 adults will take part, and the stud…

This study tracks 350 adults with uncontrolled COPD who are starting dupilumab, a medication that helps control inflammation. Over 24 months, researchers will measure changes in quality of life and monitor for side effects. The goal is to see how well dupilumab works in everyday …

This study tests a daily pill called rilzabrutinib in people aged 10 to 65 with sickle cell disease. The goal is to see if it can lower the number of painful vaso-occlusive crises (VOCs) over 52 weeks. About 192 participants will receive either the drug or a placebo. Those who co…

This study tests an experimental drug called SAR441566 in about 204 adults with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. The goal is to see if different doses can help patients achieve remission (…

This study tests an oral drug called rilzabrutinib for adults with warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system destroys red blood cells. About 90 participants will receive either the drug or a placebo for 24 weeks, then all may receive the drug f…

This study compares two injectable diabetes treatments—iGlarLixi (a combination insulin and GLP-1 drug) and Gla-100 (a standard insulin)—in Chinese adults with type 2 diabetes whose blood sugar is not well controlled with oral medications. About 678 participants will use a contin…

This study looks at whether it is safe for males aged 12 and older with severe hemophilia A to switch from their current medicine (emicizumab) to a new one called fitusiran. About 20 participants will be followed for up to 28 months to monitor side effects and blood clotting. The…

This study tests a new medicine, duvakitug, to see if it can help people with moderate to severe ulcerative colitis feel better and reach remission. About 980 adults will receive either the drug or a placebo for up to 12 weeks. The goal is to reduce bowel urgency, bleeding, and i…

This study tests a new medicine called lunsekimig in adults aged 40-80 with COPD that is not well controlled, especially those with a type of inflammation called eosinophilic. The goal is to see if it can reduce the number of moderate-to-severe flare-ups and improve breathing ove…

This study tests a drug called belumosudil in children aged 1 to 18 who have moderate-to-severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant. The disease has not improved with at least two prior treatments. The goal is to find the right dose and see if t…

This study tests an injectable medicine called dupilumab in children aged 2 to under 6 years whose asthma or wheezing is not well controlled with standard inhalers. The goal is to see if it can reduce severe asthma attacks and improve breathing safety over a year. About 90 childr…

This study tests a new gene therapy called SAR446268 for people aged 10 to 55 with myotonic dystrophy type 1, a genetic muscle disease. The therapy aims to reduce harmful RNA levels and improve muscle function. The trial has two parts: first, finding the safest dose, then testing…

This study tests an experimental drug called rilzabrutinib against a placebo in 124 adults with active IgG4-related disease, a rare condition causing painful swelling in organs. The goal is to see if the drug can prevent disease flares and reduce the need for steroids over 52 wee…

This study looks at the long-term safety and effectiveness of a drug called lunsekimig for adults with asthma. Participants who finished a previous study can join this one and receive the drug for up to 96 weeks. The goal is to see if the drug continues to help control asthma and…

This study is checking the safety of Beyfortus, a medicine to prevent RSV, in Korean children up to 2 years old. About 3,000 kids will be watched for 6 months after getting the shot. The goal is to see if any side effects happen in real-world use.

This study tests a new vaccine (PCV21) designed to protect babies against 21 types of pneumococcal bacteria, which can cause serious illnesses like pneumonia and meningitis. About 2,195 healthy infants will receive four doses of either the new vaccine or an existing one, starting…

This study follows 184 adults with moderate-to-severe atopic dermatitis (eczema) who also have anxiety or depression. All participants are already starting dupilumab as part of their regular care. Researchers will track changes in anxiety, depression, and quality of life over 6 m…

This study tests if dupilumab can reduce severe itching in adults with chronic pruritus of unknown origin (CPUO) — a condition where people itch for months with no clear cause. About 284 adults aged 18 to 90 will receive either dupilumab or a placebo for 24 weeks, alongside stand…

This study tests the safety and processing of dupilumab in 18 children and teens (6 months to under 18 years) with prurigo nodularis, a condition causing very itchy skin bumps. Participants receive the drug for 24 weeks and are monitored for side effects and how the drug moves th…

This study tests an investigational drug called itepekimab in adults with chronic sinusitis and nasal polyps that are not well controlled by standard treatments. About 210 participants will receive either the drug or a placebo for up to 52 weeks, alongside their usual nasal stero…

This study follows about 500 adults with uncontrolled COPD who are taking dupilumab as part of their regular care. Researchers will collect information on their health, symptoms, and any side effects over 36 months. The goal is to better understand the types of patients using thi…

This study is gathering information from medical records of about 60 people with stage 2 type 1 diabetes who received the drug teplizumab. The goal is to learn more about the patients' health history, how doctors monitor them, and how quickly their diabetes progresses. This is an…

This study follows 150 adults with eosinophilic esophagitis (EoE) who are starting dupilumab as part of their normal medical care in Germany. Researchers will collect information on patients' medical history, symptoms, quality of life, and any side effects over two years. The goa…

This study collects safety information from about 100 women with Pompe disease who used the medicine Nexviazyme during pregnancy or while breastfeeding, and from their babies. Researchers will watch for any health problems in mothers and track infant growth and development throug…

This study aims to describe the characteristics, treatment burden, and quality of life of 2,500 people with asthma across all severity levels. It does not test a new drug or treatment. Instead, researchers will collect data through surveys and lung function tests over time to bet…

This study follows 400 people with chronic spontaneous urticaria (long-lasting hives) who are prescribed dupilumab by their doctor. Researchers will collect information from medical records and patient surveys over 24 months to see how well the drug works in everyday life, its sa…

This study will follow 600 French adults with moderate-to-severe atopic dermatitis (eczema) who are eligible for or already taking systemic medications. Researchers will observe which treatments doctors prescribe, how long patients stay on them, and how well they follow the treat…

This study follows 900 people aged 6 and older with atopic dermatitis (eczema) who are taking dupilumab as part of their normal care. Researchers will track symptoms, quality of life, and disease control over 2 years using questionnaires and checkups. The goal is to understand ho…

This study looks at over 500,000 health records to see if doctors' diagnosis codes accurately identify chlamydia infections. Researchers will compare these codes with lab test results. The goal is to make sure electronic health data can be trusted for future chlamydia vaccine stu…

This study follows 550 people with stage 2 type 1 diabetes in the U.S. to see how their quality of life, anxiety, and diabetes management change over time. It compares those who received the drug teplizumab with those who did not. The goal is to understand the real-world benefits…

This study follows up to 10 children under 2 years old who are already receiving olipudase alfa for acid sphingomyelinase deficiency (ASMD). The goal is to monitor long-term safety and whether the body develops antibodies against the drug. No new treatment is given; researchers s…

This study screens children and teenagers (ages 1.5 to 18) who have a parent or sibling with type 1 diabetes. The goal is to find early signs of the disease, like specific antibodies in the blood, before any symptoms appear. Participants will have two visits over 13 months to che…

This study will follow 1,000 adults and teens with atopic dermatitis (eczema) who are starting or switching systemic treatments. Researchers will track which treatments are used, how well they work, and how the disease changes over 5 years. The goal is to better understand patien…